Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT02099500
Other study ID # ADI-US-CLIN-001
Secondary ID
Status Withdrawn
Phase Phase 1
First received March 19, 2014
Last updated July 19, 2017
Start date March 2014
Est. completion date June 2017

Study information

Verified date July 2017
Source Ageless Regenerative Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an open-label, non-randomized, multi center, patient sponsored study of Adipose-Derived Stromal Cell (ASC) implantation via intramuscular injections in patients who have critical limb ischemia not amenable for revascularization.

The intent of this clinical study is to answer the questions: 1) Is the proposed treatment safe and 2) Is treatment effective in improving the disease pathology of patients with diagnosed critical limb ischemia ASCs will be collected from the patient's adipose-derived tissue (body fat). Using local anesthesia, Liposuction will be performed to collect the adipose tissue specimen. The adipose tissue is then transferred to the laboratory for separation of the adipose tissue derived stem cells. In addition, peripheral blood will be collected for isolation of platelet rich plasma, which are then combined with the ASC's for intramuscular injection into the lower limb.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date June 2017
Est. primary completion date April 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Age ~ 18 years

- Existence of limb ischemia, with clinical presentation corresponding to Rutherford Categories 2-6 as defined in the reporting standards adopted by \ the Society of Vascular Surgeons, or corresponding to the Leriche-Fontaine Classification, stages II, III, or IV

- Patients with, ischemia and ischemic ulceration provided patient have angiographic evidence of vascular compromise and is not a candidate for revascularization

- Stable and on optimal medical management for > 60 days as follows:

- Clopidogrel/aspirin therapy or other anticoagulation therapy, cholesterol- lowering agent, and/or antihypertensive medication

- Hematocrit = 28.0%, White Blood Cell count =14,000, Platelet count = 50,000

- Creatinine = 2.5 mg/dL, and INR = 1.6 (unless taking warfarin) or PTT < 1.5× control (to avoid bleeding complications). INR values for patients taking warfarin will be corrected prior to the procedure

- Patient meets at least one of the following diagnostic criteria for the index limb:

1. ABI<.5mmHg

2. TcpO2 <20 mm Hg when lying down and breathing room air, if available

3. Or, nonhealing ulcer due to local arterial compromise with no opportunity for revascularization

- At least one non-healing distal extremity ischemic ulcer as confirmed by a vascular surgeon

- Up to date on all age and gender appropriate cancer screening per American Cancer Society

Exclusion Criteria:

- Female who is pregnant or nursing, or is of childbearing potential and not using a reliable method of contraception

- Any medical problems contraindicating tumescent syringe liposuction

- Life expectancy < 6 months

- Patient determined to be nonsurgical candidate due to reasons such as

1. High-risk medical conditions

2. Unstable cardiac disease

3. Stroke or transient ischemic attack leading to limitations in lower extremities or occurring within 180 days prior to the initial screening visit

4. Severe arthritis or other musculoskeletal disorder.

- Systolic blood pressure (supine) = 90 mmHg

- Resting heart rate > 100 bpm

- Poorly controlled diabetes mellitus (HgbA1c > 10%)

- Life-threatening complications of limb ischemia necessitating immediate amputation

- Uncorrected iliac artery occlusion on index side unless corrected with stent

- Extensive necrosis of the index limb or other conditions that make amputation inevitable (Rutherford Category 6)

- Active clinical infection within one week of enrollment

- Treatment with immunosuppressant drugs

- Known drug or alcohol dependence, or any other factors which will interfere with the study conduct or interpretation of the results

- Not suitable to participate in the opinion of the principal investigator

- History cancer (other than non-melanoma skin cancer or in situ cervical cancer) within five years preceding study entry

- Unwilling and/or not able to give written informed consent

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Liposuction
Liposuction using aspiration syringe and tumescent local anesthesia
Other:
Stem Cell Injection
Stem cell implantation will be performed using intramuscular injection into the affected ischemic site of interest

Locations

Country Name City State
United States Ageless Institute Miami Florida

Sponsors (1)

Lead Sponsor Collaborator
Ageless Regenerative Institute

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Change from baseline in Quality of Life King's College Hospital's Vascular Quality of Life Questionnaire 3 months, 6 months
Primary Improvement from baseline in perfusion as measured by ankle-brachial index and collateral artery number Contrast Angiography 6 months
Primary Number of adverse events reported 6 months
Secondary Improvement from baseline in improvement or resolution of ulcer or gangrene Visual assessment 3 months, 6 months
Secondary Limb Salvage Assessed with doppler to measure blood flow to the affected area. 3 months and 6 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03987061 - MOTIV Bioresorbable Scaffold in BTK Artery Disease N/A
Recruiting NCT03668353 - Recombinant SeV-hFGF2/dF Injection for PAOD Phase 1
Recruiting NCT04110964 - Evaluation of Safety and Tolerability of Libella Gene Therapy for Critical Limb Ischemia: AAV- hTERT Phase 1
Not yet recruiting NCT03994666 - Cell Therapy in Critical Limb Ischemia Phase 2
Recruiting NCT02389023 - Comparison of Prevena Negative Pressure Incision Management System vs. Standard Dressing After Vascular Surgery N/A
Not yet recruiting NCT02498080 - Drug Eluting Balloons PTA in Infra-popliteal Arteries in Patients With Critical Limb Ischemia N/A
Completed NCT02539940 - Elutax-SV Drug-eluting Balloons for Below-the-knee Treatment
Recruiting NCT02239419 - Evaluation of Carbothera in the Treatment of Foot Ulcers N/A
Recruiting NCT01938872 - Evaluating the Effectiveness of Paclitaxel-eluting Balloons for Below-the-knee Angioplasty in Patients With Critical Limb Ischemia N/A
Active, not recruiting NCT01211925 - Distal Venous Arterialisation of Ischemic Limb Phase 2/Phase 3
Completed NCT02454231 - Monocentric Trial: Stem Cell Emergency Life Threatening Limbs Arteriopathy (SCELTA) Phase 2/Phase 3
Completed NCT01758874 - Study to Explore the Effect of Lowering Blood Viscosity in Patients With Treatment-resistant Critical Limb Ischemia Phase 2
Completed NCT02475200 - Phoenix Post-Approval Registry - Using the Phoenix Atherectomy Systems
Recruiting NCT04583436 - Efficacy and Safety Comparison of the Open and Endovascular Surgical Methods for the Treatment of Long Atherosclerotic Lesions of the Femoral-popliteal Segment Below the Knee, TASC D in Patients With Critical Limb Ischemia N/A
Completed NCT04071782 - Investigating the Safety and Efficacy of the Treatment With the Selution Sirolimus Coated Balloon in TASC C and D Tibial Occlusive Disease in Patients With Critical Limb Ischemia From Singapore N/A
Completed NCT03669458 - Feasibility Clinical Trial Using the SPUR System to Demonstrate Safety and Efficacy. N/A
Not yet recruiting NCT06007469 - Pedal Acceleration Time (PAT) as a Measure of Foot Perfusion
Recruiting NCT04110327 - An All-Comers Observational Study of the MicroStentâ„¢ Peripheral Vascular Stent System in Subjects With Peripheral Arterial Disease
Completed NCT02260622 - Pilot Study to Examine the Use of Rivaroxaban After Angioplasty for Critical Limb Ischemia Phase 2
Recruiting NCT02054416 - External Compression Therapy for Secondary Prevention of Lower-Limb Loss and Cardiovascular Mortality N/A